SPRB Live signals | Maximize Profits with Getagraph.com

SELL 94248 min ago

@ $4.51

Issued: 13 Feb 2024 @ 15:35

Return: -84.46%

Previous signal: Feb 13 - 09:31

Previous signal: Buy

Return: 4.64 %

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	285 153
Average Volume	1.34M
Market Cap	28.85M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.320 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.570
ATR14	$0.00400 (0.56%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Novo Holdings A/s	Sell	465 021	COMMON STOCK
2024-03-18	Novo Holdings A/s	Sell	842 020	COMMON STOCK
2024-03-19	Novo Holdings A/s	Sell	593 000	COMMON STOCK
2024-03-20	Novo Holdings A/s	Sell	359 979	COMMON STOCK
2024-03-14	Novo Holdings A/s	Sell	1 912 316	COMMON STOCK

INSIDER POWER
3.23
Last 98 transactions
Buy: 11 294 782 \| Sell: 4 967 660

Volume Correlation

Long: 0.07 (neutral)

Short: -0.96 (very strong negative)

Signal:(54.858) Neutral

Spruce Biosciences, Inc. Correlation

10 Most Positive Correlations
DYNT	0.967
DGLY	0.954
FTFT	0.94
SLNO	0.94
SYKE	0.929
CVV	0.927
LIVE	0.925
CSWI	0.923
FELE	0.922
IPHA	0.921

10 Most Negative Correlations
MTEX	-0.906
LCAP	-0.905
AHPI	-0.899
NAKD	-0.887
PROC	-0.883
LAWS	-0.88
VERA	-0.872
GRPH	-0.869
OP	-0.868
TRIT	-0.868

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Spruce Biosciences, Inc. Correlation - Currency/Commodity

-0.16
( neutral )

0.01
( neutral )

0.00
( neutral )

0.06
( neutral )

Spruce Biosciences, Inc. Financials

Annual	2023
Revenue:	$10.09M
Gross Profit:	$10.02M (99.31 %)
EPS:	$-1.240

Q4	2023
Revenue:	$2.89M
Gross Profit:	$2.87M (99.45 %)
EPS:	$-0.240

Q3	2023
Revenue:	$3.07M
Gross Profit:	$3.06M (99.45 %)
EPS:	$-0.300

Q2	2023
Revenue:	$2.17M
Gross Profit:	$2.09M (96.58 %)
EPS:	$-0.320

Financial Reports:

No articles found.

Spruce Biosciences, Inc.

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.